What it is
Psilocybin is a tryptamine alkaloid produced by certain fungi. In research and pharmaceutical development, the term usually refers to the isolated compound—not the mushroom material that may contain it in variable amounts. The body rapidly converts psilocybin to psilocin, the compound more directly responsible for its psychoactive effects. [PubChem]
A measured quantity of isolated psilocybin is not directly interchangeable with a weight of mushroom material. Species, cultivation, storage, and the individual specimen can affect compound content.
What people often describe
There is no universal psilocybin experience. Still, recurring themes show up in personal reports, facilitator conversations, and controlled studies: intensified sensory detail, rapid emotional shifts, altered time, unusual associations, and experiences interpreted as introspective or spiritual. Pleasant and difficult moments can sit side by side. [NIDA]
Colors may feel saturated; surfaces can ripple, breathe, pattern, or take on new significance.
Joy, grief, wonder, tenderness, fear, and laughter may arrive quickly or all at once.
Minutes can feel spacious, repetitive, suspended, or difficult to place in sequence.
Some people report connection, perspective, or less separation; others feel disoriented or ungrounded.
Ideas and memories can feel unusually vivid or important, but clarity during a trip is not the same as lasting truth.
Nausea, yawning, temperature shifts, heaviness, restlessness, and changes in coordination are commonly discussed.
“Set and setting” is the old shorthand for mindset and environment. Expectations, stress, company, music, physical comfort, privacy, and the ability to ask for help can all influence how an experience unfolds. None of them guarantees a particular outcome.
How it works
After conversion to psilocin, the compound interacts with several serotonin receptors. Activity at the 5-HT2A receptor is considered central to its acute alterations in perception, emotion, and cognition. Researchers are also studying changes in large-scale brain-network communication and possible relationships between the acute experience and longer-term outcomes; those relationships remain under investigation. [PubChem]
Conditions being studied
Major depressive disorder
Several randomized trials have reported symptom reductions, while more recent results also show that outcomes are not uniformly positive across designs and populations.
Treatment-resistant depression
Phase 2 research continues. A 2026 trial reported a clinically meaningful reduction but did not meet its primary efficacy outcome.
Alcohol-use disorder
Completed and recruiting controlled studies are examining drinking outcomes when psilocybin is combined with structured therapy.
Other conditions
Research also includes serious-illness-related distress, tobacco use, obsessive-compulsive disorder, and other areas; evidence maturity varies.
“Promising” describes a research signal. It does not mean psilocybin has established medical efficacy for a condition, is appropriate for an individual, or has received regulatory approval.
Doses studied in research
Protocols vary. A Johns Hopkins randomized trial used two oral sessions—20 mg/70 kg followed by 30 mg/70 kg—within a course of supportive psychotherapy. Other controlled studies have evaluated a fixed 25 mg oral dose. [Davis et al.] [Raison et al.]
Dose information describes quantities reported in controlled medical research. It is not a recommendation for self-treatment or self-administration. Research screening, formulation, preparation, monitoring, and follow-up are part of the studied intervention.
Selected registered trials
Registry status can change. Open the official record for the latest eligibility, locations, enrollment, and study-status information.
Know the red flags before the journey
Interaction research is still thin, and “I have mixed these before” is not proof that a combination is low-risk. A medication list—including prescriptions, over-the-counter drugs, supplements, and other substances—is useful context for any guide, facilitator, pharmacist, or clinician involved. Never stop or taper a prescription just to take psilocybin without the prescriber who manages it.
Lithium + classic psychedelics
Online experience-report analysis found a strong seizure signal when lithium was combined with classic psychedelics. Oregon’s regulated psilocybin program identifies current lithium use as a contraindication. This evidence is imperfect, but the signal is serious enough to treat the combination as a major red flag. [Nayak et al.] [Oregon]
SSRIs, SNRIs, antipsychotics, mood stabilizers, and other psychiatric medicines may change intensity, response, or risk. Research protocols handle them differently; self-directed skipping or tapering can create its own harms.
MAOIs and medicines or supplements that strongly affect serotonin may change or prolong effects. Human interaction data are limited, so a pharmacist or qualified prescriber should review the specific combination.
Psilocybin can temporarily raise heart rate or blood pressure. Stimulants and other activating substances may add physical stress, agitation, or anxiety—especially when cardiovascular health is already a concern.
Polysubstance experiences are harder to predict. Alcohol, cannabis, sedatives, stimulants, and unfamiliar products can alter judgment, coordination, anxiety, nausea, or the ability to respond to distress.
Common reasons to pause, screen more carefully, or refer out
Many trials exclude people with personal—and sometimes close family—histories of psychotic or bipolar disorders.
Uncontrolled blood pressure, significant heart disease, or recent cardiovascular events commonly trigger clinical exclusions.
Evidence is limited, but epilepsy and seizure risk warrant specialist review, particularly when medications or other substances are involved.
Safety evidence is insufficient, and research protocols generally exclude pregnancy and breastfeeding.
Acute instability, suicidality, coercion, unsafe surroundings, or no reliable support changes the risk picture regardless of the substance.
Misidentified mushrooms and unverified products introduce poisoning, potency, and contamination risks that psilocybin research does not address.
Some concerns come from controlled studies, some from trial exclusion rules, and some from case reports or online experience reports. Entheodex labels that uncertainty instead of pretending every interaction has been clinically tested. [Systematic review]
Risks and research exclusions
Acute experiences can include substantial changes in perception and emotion, including fear or distress. Research protocols monitor physical and psychological responses and commonly exclude people based on medical history, medication use, or personal and family psychiatric history. [NIDA]
Anxiety or distress, headache, nausea, dizziness, and temporary cardiovascular changes may occur.
Many trials exclude people with psychotic disorders or bipolar disorders, and sometimes those with a close family history of these conditions.
Serotonergic and other psychiatric medicines may affect eligibility or require protocol-specific management. Medication changes should only be made with a qualified prescriber.
Less is known about repeated exposure, rare adverse outcomes, broader clinical populations, and unsupervised use.
United States
Federal controlled-substance status, FDA approval, research authorization, state therapeutic programs, and local decriminalization are different legal concepts. State and municipal rules may differ from federal law and can change. [DEA] [FDA]
This summary is general educational information, not legal advice. Check current rules with relevant authorities in your country, state, province, and municipality before relying on it.
Selected sources
- NIH / PubChemPsilocybin compound record and chemical identifiers ↗
- JAMA Psychiatry · 2021Davis et al. Randomized clinical trial in major depressive disorder ↗
- JAMA · 2023Raison et al. Single-dose randomized clinical trial in major depressive disorder ↗
- JAMA Psychiatry · 2026EPISODE randomized clinical trial in treatment-resistant depression ↗
- U.S. FDA · 2026Considerations for clinical investigations of psychedelic drugs ↗
- U.S. DEAPsilocybin drug fact sheet and federal scheduling ↗
- NIH / NIDAReported subjective effects and safety context ↗
- Journal of Psychopharmacology · 2024Systematic review of classic-psychedelic drug interactions ↗
- Pharmacopsychiatry · 2021Online reports involving lithium and classic psychedelics ↗
- Oregon Health AuthorityClient eligibility and safety discussion guide ↗